| First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open … P Joly, M Maho-Vaillant, C Prost-Squarcioni, V Hebert, E Houivet, S Calbo, ... The Lancet 389 (10083), 2031-2040, 2017 | 501 | 2017 |
| Blastic NK-Cell Lymphomas (Agranular CD4+ CD56+ Hematodermic Neoplasms) A Review T Petrella, M Bagot, R Willemze, M Beylot-Barry, B Vergier, M Delaunay, ... American journal of clinical pathology 123 (5), 662-675, 2005 | 367 | 2005 |
| Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases F Grange, M Beylot-Barry, P Courville, E Maubec, M Bagot, B Vergier, ... Archives of dermatology 143 (9), 1144-1150, 2007 | 317 | 2007 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The lancet oncology 22 (5), 643-654, 2021 | 289 | 2021 |
| Phonophoresis: efficiency, mechanisms and skin tolerance L Machet, A Boucaud International journal of pharmaceutics 243 (1-2), 1-15, 2002 | 205 | 2002 |
| Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients F Julia, T Petrella, M Beylot‐Barry, M Bagot, D Lipsker, L Machet, P Joly, ... British Journal of Dermatology 169 (3), 579-586, 2013 | 199 | 2013 |
| Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study T Jouary, C Leyral, B Dreno, A Doussau, B Sassolas, M Beylot-Barry, ... Annals of Oncology 23 (4), 1074-1080, 2012 | 196 | 2012 |
| Delays in diagnosis and melanoma prognosis (I): the role of patients MA Richard, JJ Grob, MF Avril, M Delaunay, J Gouvernet, P Wolkenstein, ... International journal of cancer 89 (3), 271-279, 2000 | 189 | 2000 |
| Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? S Dalle, M Beylot‐Barry, M Bagot, D Lipsker, L Machet, P Joly, ... British Journal of Dermatology 162 (1), 74-79, 2010 | 187 | 2010 |
| Effect of sonication parameters on transdermal delivery of insulin to hairless rats A Boucaud, MA Garrigue, L Machet, L Vaillant, F Patat Journal of controlled release 81 (1-2), 113-119, 2002 | 184 | 2002 |
| A high prevalence of sensitization still persists in leg ulcer patients: a retrospective series of 106 patients tested between 2001 and 2002 and a meta‐analysis of 1975–2003 data L Machet, C Couhe, A Perrinaud, C Hoarau, G Lorette, L Vaillant British Journal of Dermatology 150 (5), 929-935, 2004 | 177 | 2004 |
| Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid JC Guillaume, L Vaillant, P Bernard, C Picard, C Prost, B Labeille, ... Archives of dermatology 129 (1), 49-53, 1993 | 168 | 1993 |
| Prognostic factors of paraneoplastic pemphigus S Leger, D Picard, S Ingen-Housz-Oro, JP Arnault, F Aubin, F Carsuzaa, ... Archives of dermatology 148 (10), 1165-1172, 2012 | 166 | 2012 |
| A three-year-analysis of fixed drug eruptions in hospital settings in France N Brahimi, E Routier, N Raison-Peyron, AF Tronquoy, C Pouget-Jasson, ... European journal of dermatology 20 (4), 461-464, 2010 | 166 | 2010 |
| The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty‐seven patients M Jachiet, B Flageul, A Deroux, A Le Quellec, F Maurier, F Cordoliani, ... Arthritis & rheumatology 67 (2), 527-534, 2015 | 164 | 2015 |
| Melanoma and tumor thickness: challenges of early diagnosis MA Richard, JJ Grob, MF Avril, M Delaunay, X Thirion, P Wolkenstein, ... Archives of dermatology 135 (3), 269-274, 1999 | 163 | 1999 |
| MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 … B Dreno, JF Thompson, BM Smithers, M Santinami, T Jouary, R Gutzmer, ... The Lancet Oncology 19 (7), 916-929, 2018 | 156 | 2018 |
| High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma J Zaragoza, A Caille, N Beneton, G Bens, F Christiann, H Maillard, ... British Journal of Dermatology 174 (1), 146-151, 2016 | 153 | 2016 |
| Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas F Grange, T Petrella, M Beylot-Barry, P Joly, M D'Incan, M Delaunay, ... Blood 103 (10), 3662-3668, 2004 | 152 | 2004 |
| Delays in diagnosis and melanoma prognosis (II): the role of doctors MA Richard, JJ Grob, MF Avril, M Delaunay, J Gouvernet, P Wolkenstein, ... International journal of cancer 89 (3), 280-285, 2000 | 149 | 2000 |
